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Abstract The pancreas is a complex gland performing
both endocrine and exocrine functions. In recent years there
has been increasing evidence that both endocrine and
exocrine cells possess purinergic receptors, which influence
processes such as insulin secretion and epithelial ion
transport. Most commonly, these processes have been
viewed separately. In β cells, stimulation of P2Y1 receptors
amplifies secretion of insulin in the presence of glucose.
Nucleotides released from secretory granules could also
contribute to autocrine/paracrine regulation in pancreatic
islets. In addition to P2Y1 receptors, there is also evidence
for other P2 and adenosine receptors in β cells (P2Y2,
P2Y4, P2Y6, P2X subtypes and A1 receptors) and in
glucagon-secreting α cells (P2X7, A2 receptors). In the
exocrine pancreas, acini release ATP and ATP-hydrolysing
and ATP-generating enzymes. P2 receptors are prominent
in pancreatic ducts, and several studies indicate that P2Y2,
P2Y4, P2Y11, P2X4 and P2X7 receptors could regulate
secretion, primarily by affecting Cl− and K+ channels and
intracellular Ca2+ signalling. In order to understand the
physiology of the whole organ, it is necessary to consider
the full complement of purinergic receptors on different
cells as well as the structural and functional relation
between various cells within the whole organ. In addition
to the possible physiological function of purinergic recep-
tors, this review analyses whether the receptors could be
potential therapeutic targets for drug design aimed at
treatment of pancreatic diseases.
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Abbreviations
AC adenylate cyclase
BK big conductance K+ channel
BzATP 2′&3′-O-(4-benzoyl-benzoyl)-ATP
CFTR cystic fibrosis transmembrane regulator
CX connexin
DAG diacylglycerol
ERK extracellular signal regulated kinase
GLP-1 glucagon-like peptide-1
IK intermediate conductance K+ channel
IP3 inositol 1,4,5 triphosphate
NBC sodium bicarbonate cotransporter
NECA adenosine-5′N-ethylcarboxamide
NHE sodium hydrogen exchanger
NO nitric oxide
NTPDase nucleoside triphosphate diphosphohydrolase
PKA protein kinase A
PKC protein kinase C
PLA2 protein lipase A2
PLC phospholipase C
SK small conductance K+ channel
VIP vasoactive intestinal peptide
Structural and functional basis for pancreatic function
Endocrine cells in the islets of Langerhans constitute only
3-5% of the tissue mass of the pancreas. The islets of
Langerhans are dispersed throughout the organ and com-
prise α, β, δ and PP cells, which secrete the hormones
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glucagon, insulin and amylin, somatostatin and pancreatic
polypeptide, respectively. The bulk of the gland is exocrine,
comprising 70-90% of acinar cells and 5-25% of duct cells,
depending on the species [1–3]. Acini secrete fluid
containing NaCl and a variety of digestive enzymes
including active enzymes (α-amylase, lipase, colipase,
carboxyl ester lipase, RNAse, DNAse), zymogens (trypsin-
ogen, chymotrypsinogen, procarboxypeptidases A and B,
proelastase and proprotease E) and other proteins (e.g.
trypsin inhibitor, pancreatitis-associated protein and lithos-
tathine). This enzyme-rich secretion is led through a series
of excurrent ducts, which secrete a NaHCO3-rich fluid. The
pancreatic juice aids enzymatic breakdown of various
macromolecules in the duodenum and together with the
bile and duodenal secretions it contributes to neutralization
of acid chyme entering the duodenum.
Both endocrine and exocrine cells are regulated by
parasympathetic and sympathetic nerves, hormones, auto-
crine and paracrine mediators as well as nutrients like
glucose. The integrated function of the organ is on the one
hand due to the contribution to digestive processes in the
gastrointestinal tract, thanks to secretion of pancreatic
enzymes, and on the other hand due to contribution to
regulation of the body and cellular metabolism, thanks to
the pancreatic hormones. In the latter process, the prime
function is the production of the energy source, ATP. In
recent years it has become accepted that ATP and other
nucleotides/nucleosides have extracellular roles. They are
(1) released from cells; (2) they act extracellularly via
specific purinergic receptors as autocrine, paracrine and
neural regulators; and (3) they are hydrolysed by various
ectoenzymes. The aim of this review is to address the
question of whether such “purinergic signalling” is impor-
tant for regulation of pancreatic endocrine and exocrine
functions—both in health and disease. The focus will be on
purinergic receptors, which by virtue of a variety in
molecular structures, signalling pathways and distribution
could regulate many processes in this complex organ.
Endocrine pancreas
β cells
A peculiar feature of β cells, and also α cells, is that they
use ATP in three processes: (1) as an energy source, (2) as
an intracellular second messenger acting on K+ channels
and (3) as an extracellular regulator. The latter role was
discovered quite early in the purinergic era. In the 1960-
1970s it was reported that exogenous ATP stimulated
insulin release in various preparations of rat and rabbit
pancreas as well as in in vivo experiments performed on
man and monkey [4–7]. In 1979 Loubatieres-Mariani et al.
[6] proposed that purinergic receptors control the β-cell
function. Those early studies established that ATP and ADP
were potentiators of insulin secretion, which was initiated
by glucose entry. Purines (ATP and ADP) were more
effective than pyrimidines, and adenosine had an unusual
dose-dependent effect on insulin secretion (see below). The
following paragraphs will focus on the effects of ATP/
ADP-preferring P2 receptors and adenosine-preferring P1
receptors and extend on the basic model of insulin secretion
(Fig. 1).
P2 receptors Purinergic receptors have been studied exten-
sively in in vivo and in vitro preparations of rat, mouse and
dog pancreas, as well as on islet preparations of these, and
also on the human pancreas and several insulinoma cell
lines. In all preparations, except those originating from the
mouse pancreas (see below), ATP and ADP induced insulin
secretion in the presence of glucose. The identity of
purinergic receptors on β cells was deduced from studies
using pharmacological tools and monitoring effects on, for
example, insulin release and intracellular Ca2+ signals. ATP
and its analogues (e.g. 2-methylthio ATP, ATPγS) induced
insulin secretion, but ADP and its analogues (α,β-methy-
lene ADP, ADPβS, ADPγS) were more potent and they
required at least slightly stimulating glucose concentrations
(8.3 mM) [8–12]. These findings indicated presence of an
ADP-preferring receptor, such as the P2Y1 receptor [13].
Supporting evidence for this receptor is the finding that the
P2Y1 inhibitor MRS2179 successfully eliminated the ADP/
ATP effect on β cells. Recent studies concentrated on
developing thioester nucleotides specific for P2Y1 receptors
[11, 14, 15]. The molecular evidence for the P2Y1 receptor
was provided by cloning of the receptor from rat and mouse
insulinoma cells, i.e. RINm5F and MIN6, respectively [16].
Another P2 receptor was cloned from the human pancreas;
this turned out to be the P2Y4 receptor [17, 18], which may
originate from pancreatic ducts as well as from β cells (see
below).
Although the P2Y1 receptor may be the most important
P2Y receptor in regulating insulin secretion, there is also
evidence for other P2Y receptors [19–21], and also P2X
receptors [12, 22–24], and indeed the P2X4 receptor was
cloned from rat pancreatic islets [25]. Evidence for P2X-
type receptors was provided by intracellular Ca2+ measure-
ments. For example, in the hamster clonal β-cell line HIT,
ATP stimulated Ca2+ influx rather than Ca2+ store release,
indicating receptor-operated channels, which could be P2X-
type receptors [22]. Petit et al. [12] found on rat β cells and
RIN cells that α,β-methylene ATP (P2X receptor agonist)
had transient effects on insulin release and inhibited K+
efflux, and interestingly this happened even at non-
stimulating glucose concentrations. A similar finding was
made on human islets with α,β-methylene ATP and low
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glucose concentrations [10]. Notably, ADPβS (P2Y1
receptor agonist) first became effective when the glucose
concentration was increased from 3 to 8.3 mM, i.e. from
low to slightly stimulating glucose concentrations (Fig. 1)
[10, 12].
There are only a few immunohistochemical studies on
P2 receptor distribution in the pancreas, and they reveal an
unusual pattern [21, 26–28]. P2Y1 receptors were not
detected in rat and mouse islets, as one would have
expected from functional studies, but instead they were
found on capillaries. Clear immunolocalization of P2X7
receptors was found in α cells and transiently in β cells of
developing rat pancreas. In early non-obese diabetic mice,
P2X7 receptor-labelled cells migrated to the centre of islets,
but disappeared at the later stage, and although macro-
phages and dendritic cells invaded the islets they showed
no P2X7 receptor immunoreactivity. Also P2X1 and P2X4
receptors were localised in the islets of adult animals, but
they were absent in the neonate animals. P2Y4 receptor
immunoreactivity was detected in β cells (and α cells) and
staining seemed to increase in the islets of diabetic rats.
Very recently a new report appeared on the molecular
characterization of P2 receptors in INS-1 cells [20]. It was
shown that INS-1 cells indeed express P2Y1 receptors. In
addition, they also express P2Y2, P2Y4 and P2Y6 receptors,
which stimulate other Ca2+/PKC signalling, as well as
P2Y12 receptors, which are coupled to Gi proteins and may
have inhibitory function via the cAMP/PKA signalling.
Similar molecular characterization of human β cells and
other islet cells will be necessary for future elucidation of
pharmacological and functional profiles.
What intracellular signals elicited by purinergic receptors
in β cells could potentiate Ca2+-dependent exocytosis of
insulin? From studies mostly carried out on the insulinoma
cell line RINm5F, we learned that extracellular ATP
depolarised β cells due to closure of KATP, and depolariza-
tion elicited Ca2+ action potentials and Ca2+ oscillations
[23, 29]. Intracellular Ca2+ increase is due to (1) activation
of PLC, generation of inositol (1,4,5) triphosphate and Ca2+
mobilization from intracellular stores and (2) Ca2+ influx
via channels that are not L-type voltage-activated channels,
perhaps P2X receptors (Fig. 1) [19, 23, 24, 29–31].
Nevertheless, the ATP-induced insulin release can be
somewhat independent of extracellular Ca2+ [23, 29]. These
findings indicate that ATP exerts effect via PLC-dependent
and also PLC-independent pathways. Interestingly, when
ADPβS was used on β cells and clonal rat insulin-
producing INS-1 cells, cyclic AMP and PKA activation
enhanced insulin release [32]. Perhaps parallels could be
drawn with new studies on INS-1 cells where glucagon and
Fig. 1 Role of purinergic receptors in regulation of insulin secretion
in the β cell. Glucose enters the cell via the facilitative GLUT-2
transporter. Metabolism of glucose leads to production of ATP, which
closes the ATP-sensitive channel, KATP, comprising four Kir6.2 and
SUR1 subunits. Closure of KATP depolarises the cell membrane and
opens voltage-gated L-type Ca2+ channels and Ca2+ action potentials
are generated. Increase in the cellular Ca2+ is the triggering event that
leads to exocytosis of secretory vesicles containing insulin. Stimula-
tion of P2 receptors can increase triggering and amplification of
signals associated with the glucose effect on insulin secretion. The
P2Y1 receptors increase cellular Ca
2+ and activate PKC pathways. In
addition, the P2Y1 or other P2Y receptors can activate the cyclic AMP
pathway. Putative P2X receptors allow Ca2+/Na+ influx and membrane
depolarisation, and thereby they can elicit some insulin secretion even
at low glucose concentrations. Adenosine interacts with the A1
receptors, which inhibit the cyclic AMP pathways and thereby insulin
secretion. At high adenosine concentrations, it is postulated that some
adenosine transported into the β cell exerts metabolic effects
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glucagon-like peptide-1 (GLP-1) elicit interdependent cy-
clic AMP and Ca2+ oscillations [33]. Returning to P2Y
receptors, the question is whether one type of receptor, i.e.
P2Y1 receptor, stimulates multiple pathways or whether
another type of receptor is also involved, e.g. P2Y11
receptor, which can signal via different G proteins, Gq and
Gs [13]. Taken together, it is well established that P2Y
receptors potentiate insulin secretion by a mechanism that
involves metabolism of glucose, rise in intracellular Ca2+
and possibly cAMP (Fig. 1). The inhibitory effect on KATP
channels is not direct and extracellular, but rather via
intracellular events [34].
Let us now consider mouse β cells, which seem a little
bit peculiar with respect to P2 receptors and their effect on
insulin secretion. In 1989 Petit et al. [9] found that in
mouse β cells ADP analogues had inhibitory rather than
stimulatory effect on insulin. Poulsen et al. [35] verified the
inhibitory effect of ATP on insulin secretion and studied
cellular effects. Activity of KATP channels (measured as
whole-cell K+ currents) and exocytosis (measured as
capacitance) were inhibited by 2-methylthio ATP>AT-
P>ADP>α,β-methylene ATP>UTP, thus indicating partic-
ipation of P2Y1 receptors and probably also other receptor
types. These inhibitory effects on activity KATP channels
and exocytosis involved activation of PLA2 and calci-
neurin, respectively. Since the intracellular Ca2+ signals and
currents were intact, inhibitory action of nucleotides on the
secretory machinery lay downstream of Ca2+. Similar
inhibitory effects of ATP on insulin release were also
observed in the mouse β-cell line MIN6, which has
transcripts for P2Y4/P2Y6 receptors [36]. Together, studies
to date show that in mouse β cells and MIN6 cells, ATP is
more potent than ADP in evoking transient Ca2+ spikes
[35–37]. In comparison to rat β cells and other prepara-
tions, the question is whether mouse β cells have a different
complement of P2 receptors or whether P2Y1 receptors
have different intracellular coupling to the exocytotic
machinery. A recent study on islets isolated from P2Y1-/-
mice showed that insulin secretion was increased in the
presence of high glucose concentrations. In addition,
P2Y1-/- mice exhibited a tendency to glucose intolerance
[38]. These findings indicate that P2Y1 receptors do play
some physiological role in glucose homeostasis of the
mouse.
Adenosine receptors In 1982 Bacher et al. [39] showed on
in situ perfused dog pancreas that the adenosine analogue
NECA (adenosine-5′N-ethylcarboxamide) inhibited insulin
release when given in micromolar concentrations, but
increased it when given in millimolar concentrations.
Similarly, in mouse β cells, low adenosine concentrations
inhibited glucose-related electrical activity and insulin
release and high adenosine concentrations stimulated it
[40]. It is possible that the high-concentration effect was
due to transport of adenosine into the cell and subsequent
metabolic effects. The inhibitory effect of low-concentration
adenosine is exerted via A1 receptors [7, 19, 40], which via
Gi proteins would inhibit adenylate cyclase and thus insulin
secretion (Fig. 1). The presence of A1 receptor could also
explain some observations relating to the dual effect of ATP
on insulin secretion. That is, the stimulatory effect at low
ATP concentrations is exerted via P2Y1 and other receptors
as discussed above. In addition, ATP at high concentrations
can have inhibitory effects, because it is metabolised to
adenosine, which via A1 receptors would dominate the
insulin response [19].
α cells and δ cells
In dog and rat pancreas adenosine and analogues, e.g.
NECA, induced dose-dependent glucagon release from α
cells, presumably via A2 receptors [39, 41, 42]. These
actions were eliminated by aminophylline and theophylline.
Interestingly, Bertrand et al. [43] showed in dog pancreas
that 2-methylthio ATP, apart from inducing insulin release,
also induced glucagon release. They postulated that since
glucagon secretion was delayed with respect to insulin
secretion, and since 2-methylthio ATP can be metabolised
to adenosine, the effect on glucagon secretion was via
adenosine receptors (see Fig. 2). Similarly to β cells, also α
cells have KATP channels, which are more sensitive to ATP,
and they play a major role in electrical activity and
secretory processes [44, 45].
Regarding δ cells, there are only a few studies available.
In low glucose concentrations (4.2 mM), α,β-methylene
ADP had no effect on insulin or glucagon secretion, but it
induced somatostatin secretion from δ cells—indicating the
presence of P2 receptors [43]. A similar finding was made
in perfused dog pancreas, where a more stable analogue
ADPβS induced release of somatostatin, but not of
glucagon [46].
Source of ATP
Pancreatic islets are innervated by both the parasympathetic
and sympathetic nerves. From studies of other systems it is
known that ATP is released from presynaptic terminals
containing other transmitters such as: (1) acetylcholine and
vasoactive intestinal peptide (VIP) in some parasympathetic
nerves, (2) with noradrenaline and neuropeptide Y in
sympathetic nerves and (3) with NO and VIP in enteric
inhibitory nerves (Fig. 2) [47–49]. In the pancreas, ATP and
acetylcholine have synergistic effects on insulin release [50].
Another source of ATP and nucleotides are insulin-
containing granules of β cells [51–54]. Obermuller et al.
[55] showed that adenine nucleotides are released with a
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very short delay after stimulation, while peptides (insulin)
are released later. Using a biosensor technique, Hazama et
al. [52] detected ATP release on the cell surface of β cells
and estimated the concentration to be about 25 μM.
Importantly, glucose alone can cause ATP release, indicat-
ing that there is autocrine/paracrine signalling, which could
promote insulin release (Fig. 2). Thus, one role for released
nucleotides could be potentiation of the glucose effect and
perhaps this could explain the biphasic insulin secretion [7]
or the oscillatory release of insulin (see below). Another
role for released nucleotides could be regulation of exocrine
function (see the “Exocrine” section).
Islet as a whole—oscillations and possible role
of nucleotides
High glucose induces pulsatile insulin release. This occurs
in many species in vivo, in the isolated pancreas and in
single islets (see [56]). Insulin oscillations are accompanied
by Ca2+ oscillations and can be uncoupled in some
circumstances, e.g. in ob/ob mice, in old animals and with
hyperstimulation [57, 58]. Moreover, in type 2 diabetes, the
pulsatile pattern of insulin release is impaired [56].
Mechanisms governing oscillations are unclear. A neuro-
genic component is believed to play a role, but a recent
study showed that also coupling between β cells must be
important. Loss of connexin, CX36, changes β-cell
coupling and islet synchronization of glucose-induced
Ca2+ and insulin oscillations [59]. In addition, recent
studies indicated that also exogenous and endogenous
nucleotides may play a role in this rhythmicity. Exogenous
ATP (or ADP and 2-methylthio ATP) elicits oscillations in
the membrane potential, intracellular Ca2+ and PLC [30, 60,
61]. Interestingly, in rat β cells the P2Y1 antagonist
MRS2179 inhibited glucose-induced insulin oscillations
measured in the portal vein, but strangely it did not inhibit
Ca2+ oscillations [62].
Glucose is a stimulator of insulin release, but it usually
suppresses release of glucagon from α cells in intact islets.
Thus, in contrast to β cells, glucagon-secreting α cells
presented asynchronous Ca2+ oscillatory patterns in re-
sponse to low glucose concentrations, and this pattern was
suppressed in high glucose concentrations [63]. In a recent
study on rat preparations, where high frequency sampling
of venous effluents was used, it was shown that high
glucose induced insulin release and also glucagon release
about 180° out of phase, and this was sensitive to the
MRS2179 inhibitor [64]. One possible interpretation is that
high glucose induced release of insulin and nucleotides,
which on the one hand potentiated the effect of glucose on
β cells. On the other hand, the hydrolytic product
adenosine could then via A1 receptors on β cells down-
regulate release of insulin, and on A2 receptors of α cells it
could stimulate release of glucagon (see model in Fig. 2).
Nevertheless, for a physiologically relevant situation, the
total amounts of cyclically released insulin and glucagon
would have to be coordinated depending on the glucose
level: high glucose and ATP should favour insulin
secretion; and low glucose and adenosine would favour
glucagon release.
Fig. 2 Sources and roles of
nucleotides in a pancreatic islet.
Nucleotides are released from
nerves or from insulin-containing
granules. ATP/ADP can autore-
gulate insulin release and/or
affect coupling between β cells.
Extracellular hydrolysis by
ectoenzymes leads to production
of adenosine that could on the
one hand down-regulate insulin
secretion from β cells, and on the
other hand it could stimulate
glucagon release in α cells. High
glucose inhibits glucagon release
in α cells. The graph shows the
theoretical oscillations in insulin
and glucagon levels in the
presence of high glucose
concentrations
Purinergic Signalling (2008) 4:237–253 241
Therapeutic potentials for improving insulin secretion
Many drugs can increase insulin secretion in vitro, but only
some have a therapeutic potential for treatment of non-
insulin-dependent diabetes. The most frequently used drugs
to date are sulphonylureas and glinides, which decrease the
open probability of KATP channels, and result in depolar-
ization of the cell membrane, and the increase in cell Ca2+
leads to insulin release [61, 65–67]. The action of these
drugs is independent of plasma glucose concentrations and
therefore it may be difficult to achieve glycaemic control,
i.e. they can lead to hypoglycaemia. Since P2Y1 receptor
agonists amplify insulin release in the presence of stimu-
lating glucose concentrations, they may potentially reduce
the risk of hypoglycaemia. Intravenously and orally
administered ADPβS was a potent insulin secretagogue
and improved glucose tolerance in the in vivo rat and dog
pancreas [46, 68]. P2Y receptor agonists also amplified
secretion of insulin on an in vitro pancreas preparation from
Zucker diabetic rats [69]. In human islet preparations, P2Y
receptor agonists were also successful in inducing glucose-
dependent insulin secretion [70]. Nevertheless, it is impor-
tant to consider possible effects of P2 agonists on blood
vessels [71] and also on the exocrine pancreas (see below).
Recent efforts have led to the development of C2
substituted ATP analogues [thioester nucleotides such as
2-thioester 5′-O-(1-thiotriphosphate) adenosine derivatives],
which would be specific for P2Y1 receptors on β cells.
Fischer and collaborators found some very effective ana-
logues regarding insulin release (potent in the nanomolar
range) and stable regarding degradation by NTPDase, but
unfortunately these also had pronounced vasodilatory effects
in the rat pancreas [14, 15]. Most recently, a new generation
of 2-substituted 5′-O-(1-boranotriphosphate) adenosine ana-
logues was developed. One of these, 2-methylthio-ATP-α-B
(A isomer) was able to elicit glucose-dependent insulin
secretion with high efficacy in rats, and it had minimal effects
on pancreatic vascular resistance [11]. Thus, this analogue is
a good candidate for future therapeutic developments.
Another approach to increase insulin secretion could be
to inhibit A1 receptors on β cells. Bacher et al. [39] showed
that the methylxanthine compound aminophylline attenuat-
ed the action of adenosine in the dog pancreas. On human
subjects one study showed that aminophylline had no
influence on basal insulin secretion, it augmented glucose-
induced insulin secretion in healthy subjects, but not in
patients with type 2 diabetes [72]. In contrast, another study
on a small group of type 2 diabetic patients showed that
aminophylline stimulated insulin secretion [73]. Since
methylxanthines have many other molecular and systemic
effects, future efforts are needed to find β-cell-specific
compounds. Apart from the endocrine pancreas, adenosine
receptors in other tissues are also targets for diabetes
treatment, e.g. stimulation of A1 receptors in adipocytes
inhibits lipolysis and increases glucose metabolism, and




Pancreatic acini are well studied with respect to mechanism
and regulation of enzyme secretion, intracellular Ca2+
signalling and ion transporters involved in fluid secretion.
Compared to acini of other exocrine glands, knowledge
regarding the role of purinergic receptors in pancreatic acini
is limited [75, 76]. Reverse transcriptase polymerase chain
reaction (RT-PCR) analysis on single acini from the rat
pancreas revealed that they contain transcripts for P2X1,
P2X4, P2Y2 and P2Y4 receptors [77]. Interestingly, no
transcript for P2X7 receptors was found, although these
receptors are expressed in ducts (see below) and also in
acini of other exocrine glands [78–81]. Clearly, P2X7
receptors, which can form lytic pores under some con-
ditions, would be dangerous in pancreatic acini filled with
digestive enzymes. Their untimely activation and release
could initiate autodigestive processes, such as occurs in
pancreatitis. In this light, it will be important to establish
whether human pancreatic acini also lack P2X7 receptors.
Functional studies using intracellular Ca2+ measurements
and measurement of organic anion uptake on single cells
within acini revealed than only about 10-20% of cells
responded to extracellular ATP or UTP [77, 82]. Thus, it
seems that there are only a few cells within an acinus or a
few acini that have functional P2 receptors, and that P2
receptor-induced effects remain contained within single
cells and thereby may not have significant effect on
secretion processes as a whole. If this assumption holds, it
would be tempting to postulate that scarcity of functional
P2 receptors in acini is advantageous for the tissue that
releases significant amounts of ATP and is prone to
autodigestion (see below). However, it cannot be excluded
that receptors are not accessible or are down-regulated in
the particular rat gland preparation, or that ATP does not
reach the receptor due to efficient hydrolytic enzymes (see
below). In comparison, about 90% of acini prepared from
other exocrine glands (e.g. salivary and lachrymal glands)
using similar methods respond to ATP, although there is a
functional heterogeneity in P2X4, P2Y2 and P2Y1 recep-
tors, and these acini also express P2X7 receptors [78, 79,
81, 83–88]. It is also established in exocrine gland acini that
distribution and function of some P2 receptor is influenced
by the developmental state, innervation and duration of cell
culture [78, 87–90]. Thus, for pancreatic acini, the possible
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role of P2 receptors in short-term and long-term effects on
secretory and other processes needs further investigation.
Pancreatic ducts—native tissue
P2 receptors In contrast to pancreatic acini, pancreatic
ducts exhibit functional P2 receptors. Detailed analyses of
molecular identity and function of P2 receptors were carried
out on the rat (and guinea pig) pancreas and therefore this
will be the starting and reference point for other numerous
studies on human duct lines. In single pancreatic ducts
microdissected from the rat pancreas, ATP had a concen-
tration-dependent effect on the membrane potential and it
stimulated both Ca2+ release and Ca2+ influx with the
following potency UTP≥ATP>2-methylthio-ATP>α,β-
methylene-ATP≫adenosine [91–94]. BzATP, which is an
agonist for P2X7 and also other P2X receptors [95],
induced fully reversible Ca2+ and Na+ influx. RT-PCR
analysis revealed that rat pancreatic ducts have transcripts
for P2Y2, P2Y4, P2X4 and P2X7 receptors [94], which
agrees with studies of Ca2+ transients and other functional
assays discussed below. Luo and Muallem [96] found a
greater variety of receptors on rat pancreatic tissue,
probably reflecting differences in tissue preparation. Using
immunohistochemistry, Coutinho-Silva et al. [21, 26]
detected P2Y2 receptors on pancreatic ducts, and P2Y1 on
neonate ducts, but with given antibodies no P2X4 or P2X7
receptors were detected on the exocrine pancreas, but rather
on pancreatic islets. Further experimental approaches are
needed to resolve the discrepancy between molecular and
functional identity and immunoidentification of the P2
receptors.
Before analysing the possible role of P2 receptors in duct
function, let us summarise known secretory and regulatory
mechanisms in pancreatic ducts (Fig. 3a). The classic
secretagogues secretin and acetylcholine stimulate ductal
secretion by primary opening of CFTR (the cystic fibrosis
transmembrane regulator) Cl− channel, regulated by the
cAMP pathway, or opening of Ca2+-activated Cl− channels.
Parallel activity of various H+ and HCO3 transporters
ensures transport of HCO3 into duct lumen [97, 98]. The
driving force for anion transport is kept by opened K+
channels [91, 99–102]. Interestingly, in rat pancreatic ducts
UTP (which activates rat P2Y2 and P2Y4 receptors with
about equal efficiency) decreased the whole-cell K+
conductance and no effect on the Cl− conductance could
be detected [94]. Thus, it was predicted that these receptors
would down-regulate ductal secretion (Fig. 3b). This was in
fact found in isolated guinea pig pancreatic ducts, where the
basolateral application of UTP decreased secretion [103]. A
similar effect of UTP on secretory processes was also
detected in polarised Capan-1 cells, which are epithelial
cells derived from pancreatic adenocarcinoma [104]. RT-
PCR analysis of the single rat ducts revealed that they
express Ca2+-activated K+ channels of the intermediate
conductance (IK also known as SLO, Maxi K and
KCNMA1) and big conductance (BK also known as SK4,
KCNN4) [105]. Human IK or BK channels were co-
expressed with hP2Y2 or hP2Y4 receptors in Xenopus
oocytes and cell currents were measured. Notably, P2Y2
receptors inhibited BK channels; the other receptor/channel
combinations, such as P2Y2 and IK, P2Y4 and BK or IK,
were stimulatory. Thus, most likely on the basolateral
membrane of pancreatic ducts, the P2Y2 receptor-mediated
effect on BK channels dominates the whole-cell conduc-
tance and K+ channel inhibition down-regulates secretion
(Fig. 3b). The cellular signalling between the P2Y2 receptor
and BK is yet to be established, and recent discoveries of
P2Y2 receptor interactions with various intracellular signal-
ling pathways offer a number of possibilities [106, 107]. In
theory, the function of this P2Y2 receptor to BK interaction
would be the “brake” or “control” point in regulation of
secretion in the ductal system, perhaps sensing and
preventing distension of the duct. Other mediators, such
as substance P and atrial natriuretic factor, have been
ascribed similar protective roles since they inhibit duct
secretion [108, 109].
In contrast to BK channels, IK channel regulation by
P2Y4 or even P2Y2 receptors is stimulatory, as would be
required for secretory processes [105]. Therefore, localiza-
tion of these channels and receptors and conditions that will
favour secretory events need to be elucidated. Since
exocrine glands, including the pancreas, secrete fluid where
K+ is higher than in plasma, it is predicted that up to about
20% of the total cellular K+ conductance would increase the
secretory rate [110]. In pancreatic ducts, the circuit analysis
shows that the luminal K+ conductance contributes about
10% to the total cell K+ conductance (Fig. 3b) [99].
Let us turn to the P2X receptors in pancreatic ducts.
BzATP had effects on Ca2+ influx and membrane voltage/
current that could be ascribed to P2X7 or possibly P2X4
receptors, which were detected functionally on the luminal
membrane [94, 96]. It was not possible to detect whether
BzATP would also open Cl− channels, or stimulate
Hþ

HCO3 transport [111]. Thus, if P2X7 receptors, or
P2X4 receptors, have an effect on secretion, it may be by
means of up-regulating secretion rather than initiating it.
The intracellular mechanisms stimulated by P2X receptors
in pancreatic ducts are unknown, but they may involve
Ca2+ or Na+ influx and an independent activation of mitogen-
activated protein kinases, ERK1/2 [112]. Interestingly, in
guinea pig pancreatic ducts that were cultured overnight
injection of ATP into the lumen (or UTP) increased secretion
[103]. Possibly, this could be due to stimulation of P2X7
receptors, or other receptors such as P2Y2, P2Y4 or
adenosine receptors. Taken together, it is not known whether
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the target effect of putative P2X7 receptors are ion trans-
porters involved in secretion, as may be the case for other
exocrine glands [75], or whether effects are long term,
involving regulation of cell proliferation or cell death, as
described for some cells [95, 113]. The Raf-MEK-ERK
signalling cascade plays a crucial role in the regulation of
apoptosis, proliferation and metastasis of pancreatic cancer
[114]. We already know that other agonists, such as
neurotensin and EGF, promote DNA synthesis in pancreatic
cancer cells (Panc-1) via ERK activation [115, 116].
One of the well described effects of P2X7 receptors is
their ability to form or mediate formation of pores, which
would allow permeation of large molecules and eventually
cause cell lysis [95, 113]. One of the events precipitating
pore formation experimentally is the use of Ca2+- and
Mg2+-free solutions. Pancreatic juice normally has free
Ca2+ concentrations varying between 0.1 and 1 mM. Thus,
in a physiological situation pore formation would not be
expected on this basis. Recently, other regulators of P2X7
receptors have been proposed. The microbial peptide LL37,
from the family of cathelicidins, could also activate P2X7
receptors [117]. Although LL37 is found in salivary glands
[118] and its role in P2X7 receptor stimulation has been
discussed [119, 120], there are no reports of cathelicidins in
the pancreas. It has also been proposed that extracellular
Cl− could regulate the P2X7 receptor in parotid gland
ducts [119, 121]. Since pancreatic ducts transport Cl− and
pancreatic secretion varies in concentration of Cl−, the
effect of extracellular Cl− on luminal P2X7 it is an interest-
ing possibility.
The P2X4 receptors are widely expressed in all exocrine
glands—pancreatic acini and ducts, parotid and subman-
dibular acini and ducts [75]. Usually, the function of P2X4
receptors has been difficult to separate from P2X7 recep-
tors, except for a recent study on human parotid acini,
where it was shown that cAMP potentiates ATP-evoked
Ca2+ signalling via P2X4 receptors [81]. Overall, stimula-
tion of P2X receptors in other exocrine glands allows Na+/
Ca2+ influx and stimulation of K+ channels, Na+/H+
exchange, Na+-K+-Cl− cotransport, causes volume changes
and stimulates amylase release [75, 76]. Therefore, some
P2X receptors could be involved in genuine secretory
events in the exocrine glands.
Pancreatic ducts—cultured tissue
Numerous studies have been carried out on human pancre-
atic adenocarcinoma epithelial cell lines—Panc-1, Capan-1,
HPAF and CFPAC-1 cells. Only the first two lines express
functional CFTR; HPAF cells have low levels of CFTR and
CFPAC-1 cells are derived from a CF patient with deletion
of Phe-508 in CFTR. CFPAC-1 cells have been of special
Fig. 3 Purinergic receptors and ion transport in pancreatic ducts. a
The basic working model for pancreatic duct secretion elicited by
secretin or acetylcholine. The primary events are: opening of CFTR or
Ca2+-activated Cl− channels and opening of K+ channels that keep the
driving force on the secretion. The basolateral membrane transporters,
such as NBC or NHE (shown as a HCO3 import for simplicity), and
activity of intracellular carbonic anhydrase lead to accumulation of




Cl results in secretion of
HCO3 into the lumen, and this is accompanied by Na
+ and water
transport giving rise to NaHCO3-containing secretion. b P2 receptors
in native rat pancreatic ducts. P2Y2 receptors have the dominant effect
on BK channels, most likely on the basolateral membrane. Some
conclusions regarding BK inhibition and IK activation are also in
agreement with data on guinea pig ducts and human cell lines. c P2Y
receptors on human and canine duct epithelium. The size of lines and
arrows indicates the degree of P2Y receptor and ion channels
stimulation most commonly observed. The P2Y2 receptor inhibits
BK channels, as indicated by the dash
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interest because it is predicted that P2 receptor stimulation
could activate Ca2+-activated Cl− channels as an alternative
secretory pathway to the defective CFTR. Hence, the
agonists commonly used are ATP and UTP, and the results
are interpreted in connection with the P2Y2 receptor.
In CFPAC-1 cells, ATP or UTP stimulation increased
cellular Ca2+ and it increased Cl− efflux measured as halide
efflux, short-circuit or whole-cell current, or as a decrease
in intracellular Cl− activity (Fig. 3c) [122–126]. In addition,
ATP/UTP also stimulated HCO3 efflux, associated with
Cl

HCO3 exchange and monitored by intracellular pH
measurements [125, 126]. In some studies it was reported
that nucleotides also stimulated K+ currents [122, 125]. In
HPAF cells, which have relatively low expression of CFTR,
luminal ATP stimulated Ca2+-activated Cl− transport, and
furthermore transepithelial short-circuit current was depen-
dent on K+ channel activity [102]. Functionally, the K+
channels are seen as clotrimazole-sensitive Ca2+-activated
K+ channels and their molecular identity corresponds most
likely to IK. Interestingly, this cell line lacks Ba2+ sen-
sitivity indicating an absence of BK channels, which are
expressed in native duct cells [105]. In most studies on
cultured cells, cells were grown on coverslips and nucleo-
tides were added to the apical side. However, in a few
studies where nucleotides could be added to either the
apical/luminal side as opposed to the basolateral/serosal
side, they had a more pronounced effect from the apical
side [102, 124, 126]. In two studies nucleotides had the
following order of efficacy on stimulation of Cl− transport:
UTP≈ATP>ADP≫α,β-methylene ATP, β,γ-methylene
ATP, 2-methylene ATP [124, 127]. These data indicate the
presence of UTP-preferring receptors, such as P2Y2 or
perhaps P2Y4 [13]. Despite the relevant effects of ATP/
UTP on Cl−, HCO3 and K
+ transport described above, the
effects are very short lasting—in the order of seconds to
minutes. This may be difficult to reconcile with sustained
ductal secretion, which should last minutes to hours.
In several studies, CFPAC-1 cells were compared with
either cells with functional CFTR, such as Panc-1 or
Capan-1 cells, or with CFTR-transfected CFPAC-1 cells.
Nucleotides had a similar order of efficacy in stimulating
Cl− efflux from both CFPAC-1 cells and CFTR-corrected
CFPAC-1 cells, indicating that P2 receptor expression was
not altered [127]. In Panc-1 cells, ATP had a negligible
effect on Cl

HCO3 exchange, while it stimulated
Cl

HCO3 exchange in CFPAC-1 cells [125]. In another
study, ATP induced Cl− efflux in both Capan-1 and
CFPAC-1 cells; ATP increased Cl

HCO3 exchange in
Capan-1 cells but in CFPAC-1 cells Cl

HCO3 exchange
was low until the cells were corrected with transfected
CFTR [126]. Therefore, it is postulated that P2 receptors
could be used to restore some HCO3 secretion, but this
would not be fully effective until CFTR is also expressed.
Capan-1 cells express functional CFTR and receptors
and transporters perhaps closest to a “normal” human duct
epithelium. In polarised monolayers, ATP and UTP applied
luminally stimulated HCO3 secretion (measured as de-
crease in pHi), while applied basolaterally they inhibited
HCO3 secretion [104]. This is in agreement with studies on
rat and guinea pig pancreatic ducts (see above). RT-PCR
analysis indicates that this epithelium has transcripts for the
following receptors: P2Y1, P2Y2, P2Y4 and P2Y6 and for
P2X1, P2X4 and P2X5, but not P2X7. A recent study on the
human pancreas reveals that there are transcripts for P2X7
receptors in the tissue [128], although immunohistochemi-
cally receptors could not be localised to exocrine tissue
[21]. Nevertheless, our RT-PCR analysis on various human
duct cell lines indicates that they have a large repertoire of
P2 receptors, including the P2X7 receptor (unpublished
data).
Human duct cell lines have some characteristics of large/
main ducts, and in addition to ion transport they can also
secrete mucins. ATP induced mucin secretion in cell lines
expressing functional CFTR: Capan-1 cells, CFTR-cor-
rected CFPAC-1 cells, but not in CFPAC-1 cells [129]. It
seems that receptors other than P2Y2 (or P2Y4) are
involved in mucin secretion as the sequence of efficacy
was different to that for ion transport, i.e. ATP>ADP>
AMP>adenosine>UTP, and there was little dependence on
extracellular Ca2+. Similarly, in cultured canine main duct
epithelium mucin secretion was stimulated by ATP by both
Ca2+- and cAMP-dependent pathways [130, 131]. In
contrast to ion transport, the ATP effect on mucin secretion
was long lasting and seen over 30 min.
Cultured tissue from the canine main ducts was also used
for ion transport studies. Although the main duct is a high
electrical resistance epithelium compared to low resistance
smaller ducts, it nevertheless has a secretory phenotype.
Efflux of 125I− was stimulated by ATP, UTP, ATPγS>β,γ-
methylene ATP ≫ adenosine and ATP stimulated 86Rb+
efflux [132]. Using short-circuit measurements on polarised
epithelium, it was shown that both luminal and serosal
addition of UTP activated above Cl− and K+ conductances,
suggesting that P2Y2 receptors are expressed on both sides
of the epithelium. Low concentrations of UTP caused Ca2+
oscillation and synchronous activity of K+ currents,
presumed to be IK channels, and pHi measurements
indicated HCO3 secretion [131]. This finding supports
conclusions drawn from studies on rat and human P2Y2
receptors and IK channels [94, 105]. In addition to P2Y2
receptors, there are also P2Y11 receptors on the basolateral
membrane of canine epithelium that activate large Ca2+-
independent Cl− conductance and cAMP increases (see
Fig. 3c) [133].
Taken together studies on cultured duct epithelia indicate
that ATP/UTP, possibly via P2Y2 receptors, stimulate ion
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transport and signalling pathways, which would be consis-
tent with secretory processes. However, several issues still
need to be resolved. First, the ATP/UTP effects on mem-
brane Cl− and K+ channels are transient—thus the question
is whether full secretion could be supported. Second,
molecular identity, pharmacology and immunolocalization
of P2 (and adenosine) receptors needs to be resolved. Third,
it is not clear why presumed P2Y2 receptors behave
differently in human and canine duct epithelia compared
to rat, guinea pig ducts and expression system in oocytes
(i.e. stimulation of Cl− channels vs inhibition of BK chan-
nels). Possibly, effects of P2Y2 or P2Y4 receptors on Cl
−
channels and IK channels dominate in cultured cells with
apical exposure. Fourth, duct cell lines originate from
adenocarcinomas and/or main ducts and it is not certain
whether they have the same phenotype as smaller secretory
ducts. Fifth, we need to address the issue of tissue culture
and its effect on P2Y receptors and ion channels that they
regulate. In studies on salivary glands, it was shown that
duct obstruction, inflammation and culture markedly
increase P2Y2 receptor expression [87, 134, 135]. Also in
a recent study on human pancreas it was shown that the
pattern for expression of P2Y2 and P2X7 receptors can
change in pathological conditions like chronic pancreatitis,
pancreatic cancer and purinergic receptors on other than
epithelial cells need to be considered [128]. Lastly,
knowledge regarding the expression and physiological
function of P2X receptors is lacking for human tissue.
Adenosine receptors There are several studies on the
pancreas that have addressed the issue of adenosine receptors.
In the intact dog pancreas adenosine modulated secretion
evoked by secretin [136, 137]. Since the effects could also be
systemic, e.g. by effecting blood flow, it is not easy to
conclude whether the effect is exerted on pancreatic ducts
and which adenosine receptors are affected. Nevertheless,
using agonists and antagonists for adenosine receptors, it
was concluded that A2A receptors were involved in HCO

3
secretory response. On rat pancreatic lobules, adenosine
evoked amylase secretion; this was atropine sensitive,
therefore indicating that effects may have been mediated
by neural acetylcholine release [138]. Indeed, adenosine
response was not found on isolated acini.
Regarding human duct cells, there are some controver-
sies especially regarding A1 receptors. Eidelman et al. [139]
demonstrated that A1 receptor antagonists activated modest
Cl− efflux in CFPAC-1 cells, but had no effect in CFPAC-1
cells transfected with CFTR. This would indicate a role for
endogenous adenosine, possibly on Ca2+-activated Cl−
channels. A series of substituted derivatives of 1,3,7-
alkylxanthines was synthesised as potential activators for
Cl− efflux in these cells [140]. Among the xanthine
derivatives of diverse structure, there was no correlation
between potency in Cl− efflux and adenosine antagonism,
suggesting that stimulation of Cl− efflux was unrelated to
adenosine receptors. In fact it was later reported that
xanthines could bind to CFTR directly [141]. In addition,
no RNA for the human A1 receptor was found [140]. In a
latter study also on CFPAC-1 cells, other results were
obtained [127]. Adenosine had no effect on Cl− efflux in
normal CFPAC-1 cells, but after transfection with CFTR, it
stimulated Cl− efflux. Using inhibitors and antagonists for
adenosine receptors the results indicate that the effect was
due to stimulation of A1 and A2 (but not A2A) receptors.
Since no significant increase in cyclic AMP was measured,
the authors also suggested that the effects of adenosine may
be indirect. Nevertheless, a recent study showed that both
rat pancreatic ducts and human duct cell lines expressed
low levels of adenosine receptors A1, A2A, A2B and A3, the
most abundant being A2 receptors, and it seems that the
A2A receptor regulates anion transport [142, 143].
Origin and fate of ATP
As mentioned above, the pancreas is supplied by parasym-
pathetic and sympathetic nerves, which could be the source
of ATP and other nucleotides. In addition, rat pancreatic
acini release significant amounts of ATP. They do this in
response to mechanical stimulation and hypotonic shock,
but most importantly, they release ATP in response to
acetylcholine and cholecystokinin—the two natural acinar
secretagogues in the rat pancreas [144, 145]. It appears that
secretion is directed towards the lumen and ATP concen-
trations in the range of 20 μM were detected. Using
fluorescent markers for ATP stores, it appears that the
secretory granules in acini are a most likely site of ATP,
although other stores or other pathways for ATP release are
not excluded. Thus acini could provide ATP for the
downstream pancreatic ducts expressing P2 receptors on
the luminal membrane. In addition to acini, also pancreatic
ducts release ATP (unpublished data). They do possess
CFTR channels that have been repeatedly in and out of
favour as the ATP release channels [146, 147]. Another
possibility is that pancreatic ducts distend with over-
secretion and release ATP, which then via P2Y2 receptors
and BK channels inhibits further secretion and thus over-
distension of ducts [94, 105]. In contrast to salivary glands
that have myoepithelial cells to hold around ducts,
pancreatic ducts do not have such support and may rely
more on this self-regulation.
Given the high ATP secretion from rat pancreatic acini, it
was perhaps surprising to find that pancreatic juice
collected from the main common pancreatic/bile duct of
the rat pancreas, and also guinea pig and human pancreas,
had a low ATP content [145, 148, 149]. A study on the rat
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pancreas showed that CD39 (NTPDase hydrolysing ATP
and ADP to AMP) was present luminally on small ducts
and basolaterally on larger ducts [148]. In addition, the
pancreas secretes ATP-degrading enzymes, CD39 and
CD73 (5′-nucleotidase hydrolysing AMP to adenosine),
into the juice [145]. CD39 was in fact characterised and
purified as one of the first NTPDases from pancreatic tissue
(epithelial, endothelial and stromal cells) [150–152]. The
origin of secreted enzymes is possibly acinar, as it was
shown that CD39 was translocated from plasma membranes
and secretory granules towards the lumen and it was
secreted into the juice in a particular form, most likely as
microvesicles [148]. Along with highly active hydrolytic
enzymes, there are also ATP-generating enzymes in
pancreatic juice, adenylate kinase and nucleoside diphos-
phate kinase, capable of sequentially phosphorylating AMP
via ADP to ATP [145]. Thus, one would expect that in
pancreatic ducts there would be a nucleotide/nucleoside
profile favouring ATP and adenosine. Expected concen-
trations of ADP would be relatively low, which is
reflected also by the absence of ADP-preferring receptors
[94].
Exocrine pathophysiology and therapeutic potentials
In addition to diabetes, other diseases affecting the pancreas
are cystic fibrosis, acute and chronic pancreatitis and
pancreatic cancer. Mutations in the CFTR gene lead to
aberrant membrane transport and a wide spectrum of
diseases affecting epithelia. In the pancreas, faulty Cl−
(and HCO3 ) and fluid secretion leads to plugging of ducts
by mucus and digestive enzymes, which leads to destruc-
tion of acini, inflammation and cystic fibrosis. The main
defects in airway epithelia are decreased Cl− and fluid
secretion and thus impaired mucociliary clearance and
ensuing bacterial infections. One of the treatment strategies
for airway epithelia is to develop stable UTP analogues that
via P2Y2 receptors would stimulate Ca
2+-activated Cl−
channels as an alternative secretory pathway [153]. Clinical
trials show some success with increased mucociliary
clearance and forced expiratory volume [154]. Studies on
human duct cell lines defective in CFTR indicate that apical
application of ATP/UTP could also activate Ca2+-sensitive
Cl− channels, although the effect is short lasting. Neverthe-
less, it would seem difficult to design agonists targeted for
the pancreatic duct lumen.
Acute pancreatic injury can lead to a cascade of events
beginning with intra-pancreatic activation of zymogens,
release of cytokines and other proinflammatory mediators,
and ending with systemic inflammatory response and
multiple organ failure. The role of adenosine receptors has
been investigated in several studies on animal models of
pancreatitis. In rats, intraperitoneal administration of a
selective A1 agonist increased serum amylase and induced
morphologic changes in the pancreas characterised by
interstitial oedema and leucocyte infiltration—reminiscent
of pancreatitis changes [155]. In caerulein- and taurocholate-
induced pancreatitis, the A1 receptor antagonist significantly
reduced pancreatic oedema, although it did not improve the
acinar cell damage of the pancreas or the increase of serum
amylase. In two studies on caerulein-induced pancreatitis,
A2A receptor stimulation seemed to be protective [156, 157].
Fig. 4 Model for nucleotide
signalling in the pancreas. Pan-
creatic acini secrete ATP and
also hydrolytic enzymes (CD39
and CD73), which would
hydrolyse ATP to adenosine
(Ado). Intraluminal ATP can act
on luminal P2X and possibly
P2Y receptors, while the postu-
lated ATP release from dis-
tended ducts, as well as ATP
released from nerves and from β
cells, could act on P2Y receptors
on the basolateral side of ducts
(modified from [148])
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There was an attenuation in the activity of serum amylase,
pancreatic weight was less affected and there was a reduced
degree of pancreatic tissue damage (oedema, leucocyte
infiltration, vacuolization of acinar cells), and also pancreatic
blood flow was improved. Another type of experiment also
indicates that adenosine levels may be important. An
adenosine uptake inhibitor (KF24345) ameliorated the
severity and mortality of lethal acute pancreatitis, and this
effect was abolished by pretreatment with an A2A receptor
antagonist (ZM 341385) [158]. Taken together, these results
at the organ level indicate that endogenous adenosine might
have a cytoprotective role in the pancreas, similar to other
organs such as the heart and brain [74, 159]. Whether this can
be extended to the whole-body level is unclear, as adenosine is
a potential mediator of immunosuppression in multiple organ
failure, which can follow acute pancreatitis [160].
Recurrent attacks of acute pancreatitis are believed to
result in chronic pancreatitis, which is associated with
increased risk of developing pancreatic cancer [161, 162].
Extracellular nucleotides have been implicated as inflam-
matory and stress mediators in many pathological states and
thus it is appropriate to look at this in the human pancreas.
In a recent study of human material originating from
normal pancreas and pancreas from patients with chronic
pancreatitis and pancreatic cancer, it was shown that certain
NTPDases and P2 receptors were up-regulated [128]. In
chronic pancreatitis, CD39 and P2X7 were up-regulated on
the mRNA level and some tendencies were also seen on a
protein level. P2Y2 receptors, which were very low in
normal pancreas, were up-regulated in pancreatic cancer
(both mRNA and protein level). CD39 and CD39L1 were
also up-regulated in pancreatic cancer, and patients with
high expression of CD39 had longer post-operative survival
periods. Immunolocalization with given antibodies showed
CD39 distribution in the vasculature and stroma, the P2X7
receptor was in infiltrating leucocytes and P2Y2 in
fibroblasts adjacent to tumours. These findings implicate
distinct roles of CD39 and purinergic signalling in tissue
remodelling, fibrogenesis and perhaps tumour develop-
ment. Future studies will need to clarify apparent lack and
disagreement in immunolocalization of NTPDases [128,
163] and P2 receptors in the parenchyma of the human
pancreas and human duct cell lines as well as their molecular
identity [104]. At least for P2 receptors, numerous functional
studies on human and animal ducts show that they are
present on the epithelium (see above).
Integrated pancreatic function
Within the exocrine pancreas, there is evidence that ATP
and other components of the purinergic cascade mediate
along the acini-duct axis a short-term regulation of
secretion. Cholinergic stimulation or cholecystokinin stim-
ulation of acini causes release of ATP, and luminal ATP
may lead to up-regulation of secretin-evoked HCO3 and
fluid secretion of pancreatic ducts (Fig. 4). This scenario
would explain the long-standing observation in pancreatic
physiology—the fact that in the intact pancreas the
stimulation of acini potentiates the effect of secretin on
the production of the HCO3 -rich juice [164, 165]. Figure 4
shows the working model for how ATP, and/or hydrolytic
products as well as the associated enzymes and receptors,
could play a role as auto/paracrine regulators in the
pancreas. In addition to “within the lumen” signalling,
nerves supplying the pancreas could provide nucleotides/
nucleosides necessary for activation of purinergic receptors
on the basolateral membranes of pancreatic ducts (and to a
limited extent on pancreatic acini). In addition, there are
two other potential sources of ATP. One is ATP release
from the distended ducts, and this may lead to down-
regulation of secretion. Another supply may be from
endocrine cells. Single endocrine cells are scattered in the
epithelium of interlobular ducts. It is now becoming
accepted that there is a close anatomical contact between
islets and ducts (in addition to islet-acini), and there is an
insulo-ductal portal system [166, 167]. Functionally, several
islet hormones affect acinar and ductal secretion [166], e.g.
insulin potentiates secretin-stimulated secretion in the rat
pancreas [165]. Therefore, it is possible that ATP released
from β cells could affect closely apposed ductal epithelium.
Lastly, it is very likely that pathological increases in
extracellular nucleotides/sides levels can occur following
ductal hypertension, acinar damage and alcohol exposure,
and thus can be one of the factors contributing to
development of pancreatitis, and chronic pancreatitis is
one of the risk factors for development of pancreatic cancer.
From a therapeutic point of view, most advances have been
made with respect to finding drugs for modulating insulin
secretion. Most promising are P2Y1 receptor analogues that
stimulate glucose-dependent insulin secretion in animal
models, and thereby have therapeutic potential for treatment
of non-insulin-dependent diabetes. This review underpins
the complexity and possible interaction in purinergic
signalling in the pancreas. Therefore, in order to design
selective compounds with good potency and selectivity,
molecular subtypes and function of P2 and adenosine
receptors on endocrine and exocrine cells as well as on
pancreatic blood vessels, immune cells and pancreatic
stellate cells must be known.
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